Weiminghu medicine involved in the acquisition of Sinovac snatch shares privatization 单挑冷血总裁

Weiminghu medicine involved in the acquisition of Sinovac snatch shares privatization hot column capital flows thousands of thousands of stocks the latest Rating Rating diagnosis simulation trading client Sina Level2:A shares Sina speed Kanpan finance client: the most profitable investors in participating in competitive tender offer Sinovac snatch medicine Weiminghu shares privatization, reporter Qin Peru, editor Sun Fang A although the A-share market nearly half a year to continue to adjust, but the huge valuation gap is still attracting a large number of shares in the capital to participate in the privatization and regression. Weiminghu pharmaceutical announcement today, the company intends to participate in the Qianhai Gold Development Fund Management Company Limited (Shenzhen), HENG FENG INVESTMENTS (INTERNATIONAL) LIMITED, FUERDE GLOBAL INVESTMENT LIMITED, Beijing sinobioway Group Co., Ltd. (Shanghai) and the north side of the Klc Holdings Ltd set up by the buyer to the buyer group, group (listed on the Nasdaq, Sinovac referred to as SVA) the board submitted a preliminary non binding offer of privatization transactions and the special committee. This is a competitive tender offer. Sinovac disclosed in February 1st, the company received the chief executive officer and Saif (SAIF Partners) a preliminary non binding offer of privatization, the company chairman and CEO Yin Weidong SAIF and Partners IV L.P Affiliated Companies offer to $6.18 per share to acquire the company’s remaining shares. The quotation is Sinovac January 29th closing price premium of approximately 23.11%. Sinovac’s 2014 annual report, Yin Weidong and Saif were holding 10.84% and 18.99%, is the two largest shareholder. Weiminghu buyer group intends to participate in the pharmaceutical trading price is the preliminary offer submitted per ordinary share of $7. Notice disclosure, the purchase price of $7 per share compared to Yin Weidong and Saif submitted an offer within the proposed $6.18 per ordinary share price premium of approximately 13.3%, compared to January 29th (i.e. Sinovac received Yin Weidong and Saif’s internal offer of the previous trading day closing price premium of approximately 39.44%). Sinovac total share capital of 55 million 810 thousand shares, at a price of $7 per share calculation, the buyer group given the valuation of about $390 million. According to the disclosure, Sinovac through a wholly owned subsidiary of Sinovac biotech (Hongkong) with Beijing based Sinovac, Kexing (Dalian) vaccine technologies incorporation and the Beijing branch in microbian Technology Co. Ltd., three enterprises, research and development, vaccines and related products production and sales for the main people. As of September 30, 2015, Sinovac $204 million in total assets, net assets of $124 million, before 2015 three quarter revenue of $44 million 575 thousand, gross profit of $33 million 91 thousand, net profit -160 million. Although the profit is not ideal, but in people with the disease of Sinovac

未名医药参与收购科兴生物 抢食中概股私有化 热点栏目 资金流向 千股千评 个股诊断 最新评级 模拟交易 客户端 新浪财经Level2:A股极速看盘 新浪财经客户端:最赚钱的投资者都在用   参与竞争性要约收购科兴生物   未名医药   “抢食”中概股私有化   ⊙记者 覃秘 ○编辑 孙放   尽管A股市场近半年来持续调整,但巨大的估值差距仍吸引着众多的资本参与中概股的私有化和回归。   未名医药今日公告,公司拟参与由中金前海发展(深圳)基金管理有限公司、HENG FENG INVESTMENTS(INTERNATIONAL)LIMITED、FUERDE GLOBAL INVESTMENT LIMITED、北京北大未名生物工程集团有限公司和北大未名(上海)投资控股有限公司等组建的买方团,由买方团向科兴生物(纳斯达克上市,简称SVA)董事会及其特别委员会提交无约束力的私有化交易初步要约。   这是一次竞争性的要约收购。科兴生物2月1日披露,公司收到首席执行官与赛富基金(SAIF Partners)的初步非约束性私有化要约,公司董事长兼总裁尹卫东与SAIF Partners IV L.P附属公司提议以每股6.18美元收购该公司剩余的流通股。该报价较科兴生物1月29日收盘价溢价约23.11%。科兴生物2014年报显示,尹卫东与赛富基金分别持股10.84%和18.99%,是持股量最大的两个股东。   未名医药参与的买方团拟提交的初步要约的拟定交易价格则为每股普通股7美元。公告披露,7美元每股的购买价格相较于尹卫东和赛富基金提交的内部要约所提议的每股普通股6.18美元的报价溢价约13.3%,相较于1月29日(即科兴生物收到尹卫东和赛富基金的内部要约的前一个交易日)收盘价格溢价约39.44%。科兴生物总股本为5581万股,以7美元每股的价格计算,买方团给出的估值约为3.9亿美元。   据披露,科兴生物通过全资子公司科兴控股(香港)拥有北京科兴生物制品有限公司、科兴(大连)疫苗技术有限公司和北京科兴中维生物技术有限公司三家企业,主营人用疫苗及其相关产品的研究开发、生产和销售。截至2015年9月30日,科兴生物总资产2.04亿美元,净资产1.24亿美元,2015年前三季度实现收入4457.5万美元,毛利润3309.1万美元,净利润-160万美元。尽管盈利不太理想,但科兴生物在人用疫苗领域技术水平处于行业领军地位,2009年,公司在全球率先完成甲型H1N1流感疫苗盼尔来福.1的临床试验并获准生产。   一位接受上证报记者采访的券商人士表示,竞争性要约在境外并不罕见,未名医药参与发起收购应是有业务整合的打算。回头来看提出竞争性要约收购的买方团,六家成员公司中,北京北大未名生物工程集团有限公司是未名医药的控股股东,北大未名(上海)投资控股有限公司也由北大未名生物工程集团控股,三家公司属于关联关系,而中金前海发展等另外三家机构则均属于专业投资服务公司。另从业务来看,未名医药主营也是生物制药,并正在研发手足口病疫苗等,与科兴生物有着整合的基础。   此外,据记者查询,未名医药此前就与科兴生物有过业务合作,其参股公司(持股比例26.915%)北京科兴生物制品有限公司的控股股东正是科兴控股(香港)有限公司(持有剩余73.09%的股份),后者则是未名医药此次参与竞争性要约收购的科兴生物的全资子公司。THE_END 进入【新浪财经股吧】讨论相关的主题文章: